Skip to main content

Table 2 Outcomes for all patients

From: Azithromycin in the extremely low birth weight infant for the prevention of Bronchopulmonary Dysplasia: a pilot study

  Azithromycin Group
(n = 19)
Placebo Group
(n = 16)
p-value
Mortality-no. (%) 5 (26.3) 4 (25) 0.9
Incidence of BPD-no. (%) 9 (64.3) 10 (83.3) 0.26
Duration of Mechanical Ventilation-median (range) 10 (1–145) 16 (1–112) 0.40
Postnatal-steroid 6 (31.5) 10 (62.5) 0.05
Days of CPAP (range) 6 ± 7 6 ± 6 0.84
Grade III or IV IVH-no. (%) 5 (26) 5 (33) 0.65
PVL on HUS-no. (%) 1 (5) 3 (19) 0.20
Abnormal Transaminases (AST) 0 1 0.20
Bilirubin Peak 6.5 ± 2 6.3 ± 1.9 0.68
Days to full feeds‡ 18 ± 5 18 ± 54 0.95
Feeding intolerance*-no. (%) 5 (26) 9 (56) 0.07
Necrotizing Enterocolitis-no. (%) 0 1 (6) 0.20
Abnormal hearing screen-no. (%) 0 3 (25) 0.08
Bacterial Infection:    
Blood-no. (%) 10 (52) 6 (38) 0.35
Urine-no. (%) 1 (5) 4 (25) 0.15
CSF-no. (%) 0 2 (12) 0.20
Fungal Infection:    
Blood-no. (%) 3 (16) 2 (12) 0.78
Urine-no. (%) 0 2 (12) 0.20
CSF-no. (%) 1 (5) 0 1
Days of Antibiotics§ 10 ± 10 19 ± 21 0.10
Caffeine Therapy-no. (%) 13 (68) 10 (62) 0.71
PDA†-no. (%) 10 (52) 12 (75) 0.16
Courses of indomethacin    0.49
Median 1 1  
Interquartile range 0–1 0–2  
PDA ligated-no. (%) 3 (15) 4 (25) 0.49
Diuretics-no. (%) 6 (31) 8 (50) 0.26
Days of Diuretics 14 ± 30 21 ± 38 0.53
Bronchodilators-no. (%) 5 (26) 8 (50) 0.14
Days of Bronchodilators 10 ± 25 18 ± 24 0.34
Hospital days 67 ± 40 78 ± 50 0.47
  1. All data analysis was performed using ANOVA (mean ± sd), except for indomethacin and days of mechanical ventilation, which was analyzed using median test. *Defined as feeds being held for more than 24 hours, while on study. †Confirmed by echocardiogram. ‡Defined as when TPN was discontinued. §Excluding azithromycin.